Scholar Rock Holding Corporation $SRRK Shares Acquired by Janus Henderson Group PLC

Janus Henderson Group PLC increased its position in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) by 26.1% during the first quarter, Holdings Channel reports. The institutional investor owned 2,236,837 shares of the company’s stock after buying an additional 462,669 shares during the quarter. Janus Henderson Group PLC’s holdings in Scholar Rock were worth $109,891,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Siren L.L.C. grew its holdings in Scholar Rock by 17.0% during the 4th quarter. Siren L.L.C. now owns 10,825,013 shares of the company’s stock worth $476,842,000 after acquiring an additional 1,575,008 shares in the last quarter. Redmile Group LLC increased its position in shares of Scholar Rock by 73.7% in the 1st quarter. Redmile Group LLC now owns 9,066,621 shares of the company’s stock valued at $445,715,000 after purchasing an additional 3,845,775 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Scholar Rock by 26.7% in the 4th quarter. Wellington Management Group LLP now owns 5,759,428 shares of the company’s stock valued at $253,703,000 after purchasing an additional 1,213,541 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Scholar Rock by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 5,195,465 shares of the company’s stock valued at $228,860,000 after purchasing an additional 280,538 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Scholar Rock by 7.2% during the 4th quarter. State Street Corp now owns 4,034,434 shares of the company’s stock worth $177,717,000 after purchasing an additional 271,331 shares during the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Wedbush reiterated an “outperform” rating and set a $58.00 target price on shares of Scholar Rock in a research note on Tuesday, July 21st. HC Wainwright upped their price objective on Scholar Rock from $58.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research report on Friday, July 17th. Barclays increased their price objective on Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a research report on Thursday, June 18th. Four investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Scholar Rock has an average rating of “Buy” and an average price target of $56.21.

Scholar Rock Stock Down 3.5%

Shares of NASDAQ:SRRK opened at $47.29 on Friday. The stock has a market cap of $5.67 billion, a P/E ratio of -13.17 and a beta of 0.67. The firm has a fifty day moving average price of $50.11 and a 200 day moving average price of $47.69. The company has a debt-to-equity ratio of 0.71, a current ratio of 8.64 and a quick ratio of 8.64. Scholar Rock Holding Corporation has a 1-year low of $27.07 and a 1-year high of $58.49.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same quarter in the prior year, the business posted ($0.67) EPS. Sell-side analysts predict that Scholar Rock Holding Corporation will post -3.23 EPS for the current year.

Insider Activity

In other Scholar Rock news, Director Jeffrey S. Flier sold 3,053 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $53.88, for a total transaction of $164,495.64. Following the completion of the sale, the director directly owned 27,856 shares of the company’s stock, valued at $1,500,881.28. This represents a 9.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kristina Burow sold 3,053 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $53.74, for a total value of $164,068.22. Following the sale, the director directly owned 114,657 shares of the company’s stock, valued at approximately $6,161,667.18. This represents a 2.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 17,149 shares of company stock valued at $923,108. Insiders own 10.30% of the company’s stock.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).